24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
As in Adults, Minority Kids Hit Hardest by COVID-19Simple Test Shows Which Face Masks Are BestBeware of Hand Sanitizers Containing MethanolWhat Athletes Should Know About COVID-19, Heart Damage and Working OutCOVID-19 Causing More Stress in America Than Other Nations: SurveyWill Your Kid Play School Sports This Fall? Here's Some Guidance on Doing It SafelyScientists Call for Broader Use of Faster COVID TestsTwo Common Nutrients Might Keep Vertigo at BayPeople Are Dying, Going Blind After Drinking Hand Sanitizer, CDC WarnsMore Social Media Use, More Fake COVID NewsSkip the 'Maskne,' Not the MaskObesity Ups Odds for Severe COVID-19, But Age MattersSeven States Join Pact to Speed Coronavirus TestingStudy Casts Doubt on Value of Cholesterol DrugsCOVID-19 Fears Had Sick, Injured Americans Avoiding ERsCancer Diagnoses Plunge as Americans Avoid Screening During PandemicMysterious Paralyzing Illness in Kids Is Set to Return, CDC WarnsMany Older Americans Staying Strong in the PandemicCoronavirus Cases Now Climbing in the MidwestCould the First Drug That Slows Arthritis Be Here?Schools Can Reopen Safely If Precautions in Place, Australian Study ShowsFace Masks, Yes, But Don't Forget Hand-Washing TooEven With PPE, Risk of COVID-19 Still High for Frontline WorkersCoronavirus Pandemic Becoming Far More Widespread, Birx SaysGuard Against Lyme Disease This SummerKids 'Efficient' Transmitters as COVID-19 Raced Through a Georgia Summer CampCollege Students Will Need COVID Tests Every 2-3 Days for Campus Safety: StudyAHA News: Sustained High Blood Pressure May Damage Brain VesselsAnother Side Effect of COVID-19 -- Lasting Hearing Problems?Pandemic Could Complicate Hurricane SeasonStudy Reveals How Coronavirus Travels IndoorsNew Study Sheds Doubt on Notion Kids Aren't COVID-19 SpreadersAHA News: Are Virtual Doctor Visits Safe for Discharged Heart Failure Patients?Double Lung Transplants Save Lives of Sickest COVID PatientsGynecological Cancers Not a Risk for Severe COVID-19: Study11 States Could Face ICU Doc Shortages as Coronavirus Cases SurgeWildfire Pollution Puts Kidney Patients at RiskAmerica's Progress Against Early Cardiovascular Death Is SlowingAHA News: 5 Easy Ways to Keep Tabs on Heart HealthGene Study Shows How Coronavirus Swept Through the Diamond PrincessOne Disease Mosquitoes Don't Spread: CoronavirusU.S. Coronavirus Death Toll Surges Past 150,000Do Bedbugs Dirty the Air Inside Your Home?AHA News: New Test May Predict Who Develops Certain Type of Heart FailureLess Smoking, Drinking Means Fewer Hip Fractures for AmericansYet Another Study Finds Vaccines Are SafeCommon Diabetes Meds Linked to Higher Odds for a Serious ComplicationSurvivors' COVID Antibodies May Provide a Powerful GiftConcussion Ups Odds for Many Brain ConditionsFinal Coronavirus Vaccine Trials Get Underway
Questions and AnswersLinks
Related Topics

Diabetes

Pretomanid Approved for Treatment of Drug-Resistant TB


HealthDay News
Updated: Aug 14th 2019

new article illustration

WEDNESDAY, Aug. 14, 2019 (HealthDay News) -- Pretomanid tablets in combination with bedaquiline and linezolid have been approved for the treatment of a highly treatment-resistant type of pulmonary tuberculosis (TB), the U.S. Food and Drug Administration announced today.

The treatment combination was approved to treat adult patients with extensively drug-resistant, treatment-intolerant, or nonresponsive multidrug-resistant pulmonary TB. Dosing involves 200 mg of Pretomanid tablets orally once daily for 26 weeks, 400 mg of bedaquiline orally once daily for two weeks followed by 200 mg three times per week for 24 weeks, and 1,200 mg of oral linezolid daily for up to 26 weeks.

Researchers evaluated the safety and effectiveness of Pretomanid taken in combination with bedaquiline and linezolid in a study of 107 patients with extensively drug-resistant, treatment-intolerant, or nonresponsive multidrug-resistant pulmonary TB. At six months posttherapy, 89 percent of patients were successfully treated, which according to the FDA, exceeds the historical success rates for extensively drug-resistant TB. The most commonly reported adverse reactions included peripheral neuropathy, acne, anemia, nausea, vomiting, headache, elevated transaminases and gamma-glutamyltransferase, dyspepsia, rash, hyperamylasemia, visual impairment, hypoglycemia, and diarrhea.

The drug combination of Pretomanid and bedaquiline and linezolid should not be used in patients with hypersensitivity to bedaquiline or linezolid or those with drug-resistant tuberculosis, latent infection or extrapulmonary infection due to Mycobacterium tuberculosis, or multidrug TB that is not treatment-intolerant or nonresponsive to standard therapy.

Approval was granted to The Global Alliance for TB Drug Development.

More Information